Today: 3 May 2026
Browse Category

NYSE:LLY 15 February 2026 - 30 April 2026

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
30 April 2026
··
Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s new oral weight-loss drug Foundayo was prescribed 3,707 times in its second week on the U.S. market, well below Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period after launch. Lilly shares fell about 4% following the data, while Novo Nordisk’s U.S. shares rose nearly 6%. Foundayo was approved by the FDA on April 1 and began shipping April 6.
24 April 2026
···
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk’s Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly’s Foundayo at 3,707, according to IQVIA data cited by analysts. Novo’s shares rose $2.24 to $40.76, while Lilly’s fell $35.26 to $882.39. Novo said its oral semaglutide lowered HbA1c by 0.83 points more than placebo in a trial of adolescents with type 2 diabetes. The company plans to seek regulatory approval for pediatric use in 2026.
24 April 2026
··
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.
23 April 2026
···
Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health shares fell 1.6% to $30.52 Tuesday after Amazon launched a GLP-1 weight-management program through One Medical, intensifying competition in telehealth weight loss. Amazon said its program will offer same-day pharmacy delivery in nearly 3,000 cities and 24/7 prescription renewals. Eli Lilly and Novo Nordisk shares also declined. Hims is shifting away from compounded GLP-1s toward branded, FDA-approved drugs.
21 April 2026
·····
Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly will acquire Boston-based Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront, to expand into in vivo CAR-T cancer therapies. Kelonia’s KLN-1010, in Phase 1 for multiple myeloma, generates engineered T-cells inside the patient. The deal marks Lilly’s third Massachusetts biotech purchase in 2026. Kelonia had 62 employees and nearly ran out of cash before the offer.
21 April 2026
··
Eli Lilly to Buy Kelonia for Up to $7 Billion in Bet on Next-Gen CAR-T Cancer Therapy

Eli Lilly to Buy Kelonia for Up to $7 Billion in Bet on Next-Gen CAR-T Cancer Therapy

Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront, expanding into experimental cell therapies for blood cancer. Kelonia’s KLN-1010, in Phase 1 trials for multiple myeloma, uses in-body CAR-T technology. Lilly shares rose 2.5% after the announcement. The deal follows Lilly’s recent acquisitions as it seeks growth beyond obesity drugs.
20 April 2026
·
Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly secured a global licensing and research deal with Insilico Medicine worth up to $2.75 billion, including $115 million upfront. Lilly’s shares closed Friday at $878.24, down 2.1%. The company also reported positive late-stage results for Taltz with Zepbound in psoriatic arthritis and for eczema drug Ebglyss. Novo Nordisk launched a rival oral obesity pill in the U.S. earlier this month.
29 March 2026
··
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly said its obesity and diabetes drug candidate retatrutide met main goals in a late-stage trial, cutting A1C by up to 2% and body weight by 16.8%. Shares traded at $918.05, down 1.3% after an HSBC downgrade and concerns over U.S. price cuts. Side effects included nausea and vomiting, with a 5.1% discontinuation rate at the highest dose. Detailed results will be presented in June.
19 March 2026
···
Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket trading Thursday, after closing up 10.3% Wednesday. The rally follows a deal with Novo Nordisk that ends a patent dispute and will return FDA-approved Wegovy and Ozempic to Hims’ platform later this month. Analysts raised targets but warned branded drugs may bring lower margins. Hims also disclosed an SEC probe and a Justice Department referral.
12 March 2026
···
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly shares fell 1% Tuesday to $1,007.73, extending losses ahead of an FDA decision on its oral obesity pill expected in April. Ventyx Biosciences shareholders approved a merger with Lilly, with Nasdaq set to halt Ventyx stock after hours Tuesday and the deal expected to close before Wednesday’s open. The FDA issued warning letters to 30 telehealth firms over ads for compounded weight-loss drugs.
4 March 2026
···
Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly shares fell 2.3% to $1,028.07 Monday as health stocks lagged, despite the S&P 500 edging higher. Innovent Biologics won Chinese approval for Jaypirca, a Lilly-partnered cancer drug, after late-stage trial results. Investors remain focused on Lilly’s obesity drug pipeline and upcoming FDA decisions, with orforglipron inventory reaching $1.5 billion ahead of a possible U.S. launch.
2 March 2026
····
Eli Lilly stock price rebounds above $1,050 — what traders are watching next

Eli Lilly stock price rebounds above $1,050 — what traders are watching next

Eli Lilly shares rose 2.93% to $1,051.99 Friday, breaking a three-day slide after new trial data on its oral obesity pill orforglipron. The pill showed more side effects and drop-outs than Novo Nordisk’s rival, with 58% of patients on the higher dose reporting gastrointestinal issues. An FDA decision on orforglipron is expected in April. Lilly’s next earnings call is scheduled for April 30.
28 February 2026
·
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly shares fell 1.28% to $1,028.83 Wednesday after the FDA cleared a four-dose Zepbound KwikPen for obesity treatment. Novo Nordisk’s CagriSema showed less weight loss than Lilly’s tirzepatide in a head-to-head trial. Analysts called the gap significant for investors. Lilly said the new KwikPen will cost $299 per month at the 2.5 mg dose.
26 February 2026
···
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL shares fell 0.6% to A$153.27 Friday, ending a two-day rebound. The company disclosed a 69,497-share buyback for A$10.7 million and confirmed a new licensing deal with Eli Lilly for clazakizumab, including a $100 million upfront payment. Director Alison Watkins acquired 214 shares under a board plan. Investors are watching buyback pace and updates on the Lilly agreement next week.
20 February 2026
····
Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly reported its cancer drug Retevmo beat placebo on event-free survival in a Phase 3 trial for early-stage RET fusion-positive non-small cell lung cancer. U.S. markets are closed for Presidents Day, delaying any stock reaction until Tuesday. Lilly shares last closed at $1,040, up 0.2% Friday. Full trial data will be presented at a future medical meeting.
16 February 2026
··
1 2 3 … 12

Stock Market Today

  • Sonic Healthcare Faces Profit Slide Despite Revenue Growth, Raising Investor Concerns
    May 2, 2026, 10:23 PM EDT. Sonic Healthcare (ASX:SHL), a leading global pathology provider, has reported growing revenue over three years but a significant drop in profits. The stock now trades below its historical price-to-sales ratio, challenging the bullish investment narrative. Investors face uncertainty over whether the company can stabilise profitability amid rising debt and margin pressures. Sonic's continued dividend payments add tension between rewarding shareholders and maintaining financial flexibility for technology upgrades and acquisitions. Analysts remain divided, with some forecasting slower margin recovery and integration delays through 2029. The outlook suggests a mixed risk-reward profile as investors reassess valuation amid operational challenges and a cautious market response.

Latest article

Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

3 May 2026
Vertiv shares hit a 52-week high Friday before closing at $328.31, following a 30% jump in Q1 net sales to $2.65 billion. The company raised its 2026 outlook and recently acquired Strategic Thermal Labs, expanding its liquid cooling portfolio. Investors await further details at Vertiv’s May 19-20 conference in South Carolina.
AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

3 May 2026
AT&T closed a $6 billion sale of long-dated notes on April 30, with maturities ranging from 2033 to 2066, according to an SEC filing. The company reported first-quarter free cash flow of $2.5 billion, down from $3.1 billion a year earlier, citing higher capital investment. AT&T is preparing to close a $23 billion purchase of EchoStar spectrum licenses. CFO Pascal Desroches said net debt to adjusted EBITDA rose to 2.71 times.
JPMorgan Chase’s New Filing Shows the $31.4 Billion Number Investors Are Watching

JPMorgan Chase’s New Filing Shows the $31.4 Billion Number Investors Are Watching

3 May 2026
JPMorgan Chase reported first-quarter net income of $16.5 billion, up 13% from a year earlier, with revenue rising 10% to $49.8 billion. The bank’s SEC filing showed a $31.4 billion credit-loss allowance and noninterest expense up 14% to $26.9 billion. Nonperforming assets rose 10% to $10 billion. Shares closed Friday at $312.47, valuing the bank at about $864.8 billion.
Go toTop